🇺🇸 ABT-493/ABT-530 in United States
5 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 5
Most-reported reactions
- Lower Respiratory Tract Infection — 1 report (20%)
- Pyrexia — 1 report (20%)
- Squamous Cell Carcinoma — 1 report (20%)
- Sudden Death — 1 report (20%)
- Upper Gastrointestinal Haemorrhage — 1 report (20%)
Other Virology / Hepatology approved in United States
Frequently asked questions
Is ABT-493/ABT-530 approved in United States?
ABT-493/ABT-530 does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for ABT-493/ABT-530 in United States?
AbbVie is the originator. The local marketing authorisation holder may differ — check the official source linked above.